Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WE-FiERCE
NCT06073184Phase 2Recruiting
- Sponsor
- GynOncTrials
- Start
- Sep 2026
- Primary completion
- Feb 2029
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of semaglutide in endometrial cancer (EC) and Atypical Hyperplasia, sponsored by GynOncTrials. Primary endpoint: Complete Pathologic Response at 48 weeks. Started Sep 2026; status: recruiting.
02
Drugs
03
Conditions
endometrial cancer (EC)Atypical Hyperplasia
Beyond the preview
Go deeper on NCT06073184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06073184.